Systemic Anti-Cancer Therapy (SACT) Guidelines for Upper GI Cancer

Date: 
1 Apr 2017
Source: 
Northern Ireland Cancer Network
Audience: 
Patients and public
Professionals
Type of resource: 
Guidance

Affecting approximately 13,500 people per year, oesophago-gastric cancer is the fifth most common malignancy in the United Kingdom and fourth most common cause of cancer death. The incidence of adenocarcinomas of the lower oesophagus and gastro-oesophageal junction is increasing. Prognosis for most patients diagnosed with oesophago-gastric cancer remains poor, with overall 5-year survival rates being approximately 7% for oesophageal and 13% for gastric cancer [1].

In Northern Ireland 185 cases of oesophageal cancer were diagnosed in 2011, with a 1-year overall survival (OS) rate of 43.5% and 5 year OS rate of 19%. In the same year there were 236 cases of gastric cancer diagnosed; 1 and 5-year OS rates are 40.4% and 18.4% respectively [2].

This document provides guidance on treatment of patients with oesophagogastric cancer acknowledging that individual patient factors need to be considered and where possible patients should be offered the opportunity to participate in clinical trials.